Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
Blood cancer immunotherapy Sellas passes clinical trial
Business

Blood cancer immunotherapy Sellas passes clinical trial

jack colman
By jack colman
November 17, 2026 2 Min Read
Comments Off on Blood cancer immunotherapy Sellas passes clinical trial

Adam Feuerstein is a senior biotechnology writer and columnist, reporting on the intersection of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotechnology podcast The Readout Loud and author of the Adam’s Biotech Scorecard newsletter. You can reach Adam on Signal at stataf.54.

It seems I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.

On Tuesday, Sellas said the treatment, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with advanced acute myeloid leukemia (AML) – a result that met the primary endpoint of a phase 3 clinical trial, the company said.

Blood cancer immunotherapy Sellas passes clinical trial

Blood cancer immunotherapy Sellas passes clinical trial

STATPlus: Long-delayed Sellas immunotherapy study to end in failure

In a column published in September, I predicted that galinpepimut would fail to prolong survival in the phase 3 study.

Exclusive STAT+ story

Already have an account? Log in

STAT+

STAT+

This article is reserved for STAT+ subscribers

Unlock this article, plus in-depth analysis, newsletters, premium events and news alerts.

Already have an account? Log in

See all packages

To read the rest of this story, subscribe to STAT+.

Subscribe

Gn bussni

Views: 2
jack colman
Author

jack colman

**Jack** is a staff journalist and digital content writer at **DailyVoxa**, specializing in breaking news, technology, artificial intelligence, business, and global affairs. He is passionate about transforming complex topics into clear, accurate, and engaging stories that help readers stay informed.With a strong focus on fact-based reporting and thorough research, Jack monitors developing events, analyzes reliable sources, and delivers timely news with clarity and context. His work emphasizes accuracy, transparency, and editorial integrity while avoiding sensationalism.At DailyVoxa, every article written by Jack follows the publication's Editorial Policy, Fact-Checking Policy, and Ethics Policy. He is committed to providing trustworthy journalism that empowers readers with reliable information and meaningful insights into the stories shaping the world.

Follow Me
Other Articles
California prosecutors pursue Gavin Newsom to stop death penalty commutations | California
Previous

California prosecutors pursue Gavin Newsom to stop death penalty commutations | California

Warner Bros. and Paramount Animation Create Executive Leadership Group
Next

Warner Bros. and Paramount Animation Create Executive Leadership Group

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.